Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1657751

registered interest
date	04/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Ian Harvey
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when Mr Ian Harvey, the former medical director at the Countess of Chester Hospital, was last employed (a) within the NHS and (b) an organisation overseen by his Department.
tabling member constituency	Slough
tabling member printed	Mr Tanmanjeet Singh Dhesi
uin	197489
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>National Health Service staff records are not held centrally by the Department.</p> answering member constituency Colchester answering member printed Will Quince question first answered 08/09/2023 13:41:44 answering member 4423 label Biography information for Will Quince previous answer version 91960 answering member constituency Colchester answering member printed Will Quince answering member 4423 label Biography information for Will Quince
tabling member	4638 label Biography information for Mr Tanmanjeet Singh Dhesi

1658010

registered interest
date	04/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Neurodiversity: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many children were (a) on a waiting list for an assessment and (b) waiting for a diagnosis for (i) attention deficit hyperactivity disorder and (ii) Autism spectrum disorder on 1 September 2023.
tabling member constituency	Stevenage
tabling member printed	Stephen McPartland
uin	197652
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>Data on the number of children on a waiting list for an assessment for attention deficit hyperactivity disorder (ADHD) assessments and waiting for a diagnosis is not held centrally but may be held locally by individual National Health Service trusts. The Department is investigating options for improving data collection and reporting on waiting times for ADHD assessments and diagnoses, to help improve access to ADHD assessments in a timely way and in line with the NICE guideline on ADHD.</p><p>With respect to autism, NHS England publishes data on how many people are waiting for an autism diagnosis and for how long, which provides useful information nationally and locally to support local areas to improve their performance and to reduce assessment and diagnosis waiting times.</p><p>The statistics published on 8 June 2023 provide data up to 31 March 2023. Of the total 157,579 patients with an open referral for suspected autism (diagnosis not yet complete) in March 2023, 92,622 were aged zero to 17 years. 6,940 of this age group with an open referral received a first contact appointment within 13 weeks. Data on children and young people in this dataset is expected to be an underestimate. The next data release will be published on 14 September.</p><p>The current reported autism data comes from the Mental Health Services Data Set (MHSDS) only. Several providers of MHSDS data were affected by a cyber incident which impacted the data for August 2022 onwards. Data presented for August 2022 onwards are imputed estimates based on data from providers not impacted by the cyber incident. The trends and activity reported by these providers are, for the most part, reflective of the providers who were impacted by the cyber incident. However, caution should be used when interpreting these statistics.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 08/09/2023 13:36:26 answering member 4492 label Biography information for Maria Caulfield previous answer version 91975 answering member constituency Lewes answering member printed Maria Caulfield answering member 4492 label Biography information for Maria Caulfield
tabling member	4093 label Biography information for Stephen McPartland

1655778

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospitals: Pseudomonas
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of people who have contracted Pseudomonas whilst staying in hospital in each of the last 10 years for which data is available.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	195631
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>The UK Health Security Agency (UKHSA) advises in preventing outbreak of infections such as pseudomonas in hospitals to the Department, National Health Service national, regional, and local teams, including commissioners and providers. This is done through collecting and publishing data and supporting in development and updating of Infection Prevention Control (IPC) guidance, as well as providing independent IPC, decontamination, and epidemiology expertise. This also includes provision of subject matter and health protection experts such as Consultants in Public Health Medicine who can assist healthcare providers in the control of protracted and difficult outbreaks and can offer peer support visits, and specialist and reference microbiology services accessible to all healthcare providers in the United Kingdom.</p><p>UKHSA runs surveillance of <em>Pseudomonas aeruginosa </em>bloodstream infections and publishes case numbers by trust and onset setting, monthly, quarterly, and annually. UKHSA also produces a quarterly epidemiological commentary which presents trends in Gram-negative bacteraemia (including <em>P. aeruginosa</em>) over time.</p><p>UKHSA publishes data on <em>Pseudomonas aeruginosa bacteraemia </em>on a monthly, quarterly, and annual basis. This includes epidemiological commentaries, which explain the data and put the results in context. Further information is available at the following link:</p><p><a href="https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary/annual-epidemiological-commentary-gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-up-to-and-including-financial-year-2021-to-2022" target="_blank">https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary/annual-epidemiological-commentary-gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-up-to-and-including-financial-year-2021-to-2022</a></p><p> </p><p>The following table shows the number of hospital onset cases of <em>P. aeruginosa</em> since mandatory surveillance began in 2017/18.</p><table><tbody><tr><td><p>Financial year</p></td><td><p>All reported cases</p></td><td><p>Hospital onset cases</p></td></tr><tr><td><p>2017/2018</p></td><td><p>4,308</p></td><td><p>1,626</p></td></tr><tr><td><p>2018/2019</p></td><td><p>4,186</p></td><td><p>1,518</p></td></tr><tr><td><p>2019/2020</p></td><td><p>4,345</p></td><td><p>1,581</p></td></tr><tr><td><p>2020/2021</p></td><td><p>4,291</p></td><td><p>1,670</p></td></tr><tr><td><p>2021/2022</p></td><td><p>4,334</p></td><td><p>1,626</p></td></tr></tbody></table><p> </p><p><strong> </strong></p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 195632 question first answered 08/09/2023 13:20:20 answering member 4492 label Biography information for Maria Caulfield
tabling member	253 label Biography information for Mr Laurence Robertson

1655779

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Hospitals: Pseudomonas
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to prevent outbreaks of pseudomonas in hospitals; and if he will make a statement.
tabling member constituency	Tewkesbury
tabling member printed	Mr Laurence Robertson
uin	195632
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>The UK Health Security Agency (UKHSA) advises in preventing outbreak of infections such as pseudomonas in hospitals to the Department, National Health Service national, regional, and local teams, including commissioners and providers. This is done through collecting and publishing data and supporting in development and updating of Infection Prevention Control (IPC) guidance, as well as providing independent IPC, decontamination, and epidemiology expertise. This also includes provision of subject matter and health protection experts such as Consultants in Public Health Medicine who can assist healthcare providers in the control of protracted and difficult outbreaks and can offer peer support visits, and specialist and reference microbiology services accessible to all healthcare providers in the United Kingdom.</p><p>UKHSA runs surveillance of <em>Pseudomonas aeruginosa </em>bloodstream infections and publishes case numbers by trust and onset setting, monthly, quarterly, and annually. UKHSA also produces a quarterly epidemiological commentary which presents trends in Gram-negative bacteraemia (including <em>P. aeruginosa</em>) over time.</p><p>UKHSA publishes data on <em>Pseudomonas aeruginosa bacteraemia </em>on a monthly, quarterly, and annual basis. This includes epidemiological commentaries, which explain the data and put the results in context. Further information is available at the following link:</p><p><a href="https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary/annual-epidemiological-commentary-gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-up-to-and-including-financial-year-2021-to-2022" target="_blank">https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary/annual-epidemiological-commentary-gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-up-to-and-including-financial-year-2021-to-2022</a></p><p> </p><p>The following table shows the number of hospital onset cases of <em>P. aeruginosa</em> since mandatory surveillance began in 2017/18.</p><table><tbody><tr><td><p>Financial year</p></td><td><p>All reported cases</p></td><td><p>Hospital onset cases</p></td></tr><tr><td><p>2017/2018</p></td><td><p>4,308</p></td><td><p>1,626</p></td></tr><tr><td><p>2018/2019</p></td><td><p>4,186</p></td><td><p>1,518</p></td></tr><tr><td><p>2019/2020</p></td><td><p>4,345</p></td><td><p>1,581</p></td></tr><tr><td><p>2020/2021</p></td><td><p>4,291</p></td><td><p>1,670</p></td></tr><tr><td><p>2021/2022</p></td><td><p>4,334</p></td><td><p>1,626</p></td></tr></tbody></table><p> </p><p><strong> </strong></p> answering member constituency Lewes answering member printed Maria Caulfield grouped question UIN 195631 question first answered 08/09/2023 13:20:21 answering member 4492 label Biography information for Maria Caulfield
tabling member	253 label Biography information for Mr Laurence Robertson

1655803

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Vaccination: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to A review of the Vaccine Taskforce, published by his Department on 29 August 2023, what additional vaccine production capacity, of any type, has been secured as a result of the investments made (a) by the Vaccine Taskforce and (b) subsequently by the Office for Life Sciences, as described in the report.
tabling member constituency	Warley
tabling member printed	John Spellar
uin	195638
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>Through the Vaccine Taskforce, over £405 million was invested in the United Kingdom’s vaccine manufacturing capabilities across several modalities, to ensure a robust response to COVID-19 and future health emergencies. In December 2022 the Government signed a ten-year strategic partnership with Moderna which will have the capacity to produce up to 250 million cutting-edge mRNA vaccines per year onshore in the event of a pandemic. In May this year, the Government announced a Biomanufacturing Fund, worth up to £38 million, to incentivise investment in commercial-scale vaccines and biotherapeutics manufacturing.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 08/09/2023 14:12:09 answering member 4492 label Biography information for Maria Caulfield
tabling member	318 label Biography information for Lord Spellar

1655804

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Vaccination: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to his Department’s paper A review of the Vaccine Taskforce, published on 29 August 2023, what funds the Office for Life Sciences has to invest in additional vaccine production capacity in the UK in order to achieve the onshoring programme objective set for the Vaccines Taskforce.
tabling member constituency	Warley
tabling member printed	John Spellar
uin	195639
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>Through the Vaccine Taskforce, over £405 million was invested in the United Kingdom’s vaccine manufacturing capabilities across several modalities, to ensure a robust response to COVID-19 and future health emergencies. In December 2022 the Government signed a ten-year strategic partnership with Moderna which will have the capacity to produce up to 250 million cutting-edge mRNA vaccines per year onshore in the event of a pandemic. In May this year, the Government announced a Biomanufacturing Fund, worth up to £38 million, to incentivise investment in commercial-scale vaccines and biotherapeutics manufacturing.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 08/09/2023 14:13:16 answering member 4492 label Biography information for Maria Caulfield
tabling member	318 label Biography information for Lord Spellar

1655848

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Dental Services: Care Homes
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of dental treatment provided to patients requiring treatment within a (a) care home and (b) similar care setting.
tabling member constituency	Great Yarmouth
tabling member printed	Sir Brandon Lewis
uin	195957
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>Specialised dental services are in place to provide dental treatment in several settings including care homes. The frequency of dental checks will be determined by dentists on an individual basis.</p><p>NHS England is responsible for commissioning primary care dental services, including domiciliary care. Many of the dentistry commissioning functions undertaken by NHS England transferred to integrated care boards (ICBs) in April 2023. ICBs are responsible for meeting the needs of their local population by working with patient groups. Domiciliary care may be delivered by any dentist holding a contract to deliver general dental services or it may be specifically commissioned locally as an additional service. NHS England is working very closely with stakeholders, inclusive of the Care Quality Commission and Healthwatch England, to ensure that patients receive the appropriate care within the appropriate setting.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 08/09/2023 10:42:44 answering member 4679 label Biography information for Neil O'Brien
tabling member	4009 label Biography information for Sir Brandon Lewis

1655849

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS 111: Dental Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what data his Department holds on the number and proportion of individuals contacting the NHS 111 helpline (a) for medical advice on dental health and (b) to request dental treatment.
tabling member constituency	Great Yarmouth
tabling member printed	Sir Brandon Lewis
uin	195958
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>NHS England publishes the Integrated Urgent Care Aggregate Data Collection monthly which is available at the following link:</p><p><a href="https://www.england.nhs.uk/statistics/statistical-work-areas/iucadc-new-from-april-2021/" target="_blank">https://www.england.nhs.uk/statistics/statistical-work-areas/iucadc-new-from-april-2021/</a></p><p>This includes data on the number of callers to NHS 111 who were recommended to contact or speak to a dental practitioner. In June 2023, the latest data available, 85,593 callers to 111, 6.6% of all callers, were recommended to contact or speak to a dental practitioner.</p> answering member constituency Harborough answering member printed Neil O'Brien question first answered 08/09/2023 10:44:32 answering member 4679 label Biography information for Neil O'Brien
tabling member	4009 label Biography information for Sir Brandon Lewis

1655861

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Gene Therapies
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 July 2023 to Question 192548 on Gene Therapies, how many of the advanced therapeutic medicinal products evaluated by the National Institute for Health and Care Excellence that have been recommended for use were gene therapies appraised through the Single Technology Appraisal pathway.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	195970
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>As of 5 September 2023, the National Institute for Health and Care Excellence has made positive recommendations on eight out of the nine gene therapy medicinal products it has evaluated using its single technology appraisal process.</p> answering member constituency Colchester answering member printed Will Quince question first answered 08/09/2023 12:02:28 answering member 4423 label Biography information for Will Quince
tabling member	4398 label Biography information for Chris Green

1655863

registered interest
date	01/09/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Influenza: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department plans to ask the Joint Committee on Vaccination and Immunisation to update the baseline modelling and assumptions it uses to make decisions on the cost-effectiveness of vaccinating specific age cohorts against seasonal influenza.
tabling member constituency	Bolton West
tabling member printed	Chris Green
uin	195972
answer	answer is ministerial correction date of answer 08/09/2023 answer text <p>For the Joint Committee on Vaccination and Immunisation to formally revisit the cost-effectiveness of vaccinating specific age cohorts against seasonal influenza, an up-to-date impact and cost effectiveness analysis would be required, and the UK Health Security Agency is in the process of updating the influenza model using more recent data, including accounting for changes due to the pandemic.</p><p>There is currently uncertainty on any longer-term changes because of the pandemic to social contact patterns and the activity of flu in the population for a fully robust update to cost effectiveness analysis in the short term.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 08/09/2023 14:16:55 answering member 4492 label Biography information for Maria Caulfield
tabling member	4398 label Biography information for Chris Green